Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide

MLA

S, Ohie, et al. “Cisplatin Sensitivity of Ovarian Cancer in the Histoculture Drug Response Assay Correlates to Clinical Response to Combination Chemotherapy with Cisplatin, Doxorubicin and Cyclophosphamide.” Anticancer Research, vol. 20, no. 3B, Aug. 2000. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........78b8d06b1922363d7d9061053fe0bcfa&authtype=sso&custid=ns315887.

APA

S, O., Y, U., A, K., Y, K., D, A., S, N., A R, M., & R M, H. (2000). Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Research, 20(3B).

Chicago

S, Ohie, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa A R, and Hoffman R M. 2000. “Cisplatin Sensitivity of Ovarian Cancer in the Histoculture Drug Response Assay Correlates to Clinical Response to Combination Chemotherapy with Cisplatin, Doxorubicin and Cyclophosphamide.” Anticancer Research 20 (3B). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........78b8d06b1922363d7d9061053fe0bcfa&authtype=sso&custid=ns315887.